MedTrace Logo

Heparin Binding Protein in Patients With Acute Respiratory Failure Treated With GCSF (Filgrastim)

NCT01713309 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2012-10-29

No results posted yet for this study

Summary

This is a study of plasma HBP -levels of a previously published trial of G-CSF in critically ill patients (Pettila et al. Critical Care Medicine 2000). The original study was a prospective, randomised, double-blind, placebo-controlled trial of filgrastim in patients with acute respiratory failure requiring intubation. In this substudy, the investigators evaluated the effect of filgrastim on HBP -concentrations in critically ill patients.

Conditions

  • Acute Respiratory Failure
  • Critically Ill

Interventions

DRUG

Filgrastim

Filgrastim 300 ug daily for 7 days, subcutaneously.

Sponsors & Collaborators

  • The Swedish Research Council

    collaborator OTHER_GOV

  • Helsinki University Central Hospital

    lead OTHER

Principal Investigators

  • Ville Pettila, MD, PhD · Helsinki University Central Hospital

  • Kirsi-Maija Kaukonen, MD, PhD · Helsinki University Central Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1996-01-31
Primary Completion
1998-06-30
Completion
1998-09-30

Countries

  • Finland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01713309 on ClinicalTrials.gov